Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study

Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study

Background: Dupilumab, a human monoclonal anti-interleukin (IL)-4Ra antibody blocks the shared receptor component of IL-4 and IL-13, drivers of type 2 inflammation. Dupilumab is approved for severe/refractory asthma inadequately controlled by existing therapies, but knowledge of its effect on real-w...

Full description

Bibliographic Details
Main Authors: Koichi Fukunaga, Etsuko Tagaya, Masato Ishida, Yoshinori Sunaga, Ryuji Koshiba, Akihito Yokoyama
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Allergology International
Subjects:
Adrenal cortex hormones
Asthma
Disease progression
Dupilumab
Retrospective study
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893023000394

Internet

http://www.sciencedirect.com/science/article/pii/S1323893023000394

Similar Items